Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 29

1.

Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors.

Schimmer AD, Thomas MP, Hurren R, Gronda M, Pellecchia M, Pond GR, Konopleva M, Gurfinkel D, Mawji IA, Brown E, Reed JC.

Cancer Res. 2006 Feb 15;66(4):2367-75.

2.

Specific resistance upon lentiviral TRAIL transfer by intracellular retention of TRAIL receptors.

Wenger T, Mattern J, Penzel R, Gassler N, Haas TL, Sprick MR, Walczak H, Krammer PH, Debatin KM, Herr I.

Cell Death Differ. 2006 Oct;13(10):1740-51. Epub 2006 Feb 10.

3.

Response rate of fibrosarcoma cells to cytotoxic drugs on the expression level correlates to the therapeutic response rate of fibrosarcomas and is mediated by regulation of apoptotic pathways.

Lehnhardt M, Klein-Hitpass L, Kuhnen C, Homann HH, Daigeler A, Steinau HU, Roehrs S, Schnoor L, Steinstraesser L, Mueller O.

BMC Cancer. 2005 Jul 7;5:74.

4.

Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.

Hyer ML, Croxton R, Krajewska M, Krajewski S, Kress CL, Lu M, Suh N, Sporn MB, Cryns VL, Zapata JM, Reed JC.

Cancer Res. 2005 Jun 1;65(11):4799-808.

5.

Mechanisms of resistance to TRAIL-induced apoptosis in cancer.

Zhang L, Fang B.

Cancer Gene Ther. 2005 Mar;12(3):228-37. Review.

PMID:
15550937
6.

Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.

Jin H, Yang R, Fong S, Totpal K, Lawrence D, Zheng Z, Ross J, Koeppen H, Schwall R, Ashkenazi A.

Cancer Res. 2004 Jul 15;64(14):4900-5.

7.

TRAIL and apoptosis induction by TNF-family death receptors.

Wang S, El-Deiry WS.

Oncogene. 2003 Nov 24;22(53):8628-33. Review.

PMID:
14634624
8.

PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2.

Frese S, Pirnia F, Miescher D, Krajewski S, Borner MM, Reed JC, Schmid RA.

Oncogene. 2003 Aug 21;22(35):5427-35.

PMID:
12934102
9.

Protein kinase C modulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by targeting the apical events of death receptor signaling.

Harper N, Hughes MA, Farrow SN, Cohen GM, MacFarlane M.

J Biol Chem. 2003 Nov 7;278(45):44338-47. Epub 2003 Aug 14.

11.

Death receptors and melanoma resistance to apoptosis.

Ivanov VN, Bhoumik A, Ronai Z.

Oncogene. 2003 May 19;22(20):3152-61. Review.

PMID:
12789291
12.

Programmed cell death: many ways for cells to die decently.

Jäättelä M.

Ann Med. 2002;34(6):480-8. Review.

PMID:
12523503
14.
15.

Targeting death and decoy receptors of the tumour-necrosis factor superfamily.

Ashkenazi A.

Nat Rev Cancer. 2002 Jun;2(6):420-30. Review. No abstract available.

PMID:
12189384
16.

Apoptosis-based therapies.

Reed JC.

Nat Rev Drug Discov. 2002 Feb;1(2):111-21. Review.

PMID:
12120092
17.

Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma.

Griffith TS, Fialkov JM, Scott DL, Azuhata T, Williams RD, Wall NR, Altieri DC, Sandler AD.

Cancer Res. 2002 Jun 1;62(11):3093-9.

19.

Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance.

Thakkar H, Chen X, Tyan F, Gim S, Robinson H, Lee C, Pandey SK, Nwokorie C, Onwudiwe N, Srivastava RK.

J Biol Chem. 2001 Oct 19;276(42):38361-9. Epub 2001 Jul 18. Retraction in: J Biol Chem. 2002 Aug 16;277(33):30408.

20.

Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL.

Bodmer JL, Meier P, Tschopp J, Schneider P.

J Biol Chem. 2000 Jul 7;275(27):20632-7.

Supplemental Content

Support Center